GlassScriptPhysician profile
Dennis W Dietrich
NPI 1871677245
$140,259.70
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $28K · 2021: $34K · 2022: $32K.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $92,827.47 | 2019-2022 | |
| Genzyme Corporation | $37,856.10 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $7,382.88 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $397.07 | 2019-2021 | |
| Celgene Corporation | $384.20 | 2020-2021 | |
| Genentech USA, INC. | $267.67 | 2019-2021 | |
| Sentynl Therapeutics, INC. | $219.00 | 2020 | |
| Amgen INC. | $210.21 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $143.57 | 2019-2021 | |
| Sarepta Therapeutics, INC. | $104.51 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $76.10 | 2019-2020 | |
| Emd Serono, INC. | $63.95 | 2019 | |
| Ucb, INC. | $42.74 | 2019 | |
| Lilly USA, LLC | $36.51 | 2019-2021 | |
| Abbvie INC. | $36.46 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $31.25 | 2020 | |
| Genentech, INC. | $29.18 | 2020 | |
| Tanabe Pharma America, INC. | $24.66 | 2021 | |
| Sunovion Pharmaceuticals INC. | $23.48 | 2021 | |
| Acorda Therapeutics, INC | $20.16 | 2019 | |
| Lundbeck LLC | $19.39 | 2020 | |
| Allergan, INC. | $16.73 | 2020 | |
| Upsher-Smith Laboratories LLC | $16.06 | 2020 | |
| Amneal Pharmaceuticals LLC | $12.21 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $10.99 | 2020 | |
| Merck Sharp & Dohme LLC | $7.15 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Dietrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.